Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350280 | 0.87 | SLC6A9 (0.45) | SLC6A9SLC6A5 | |
| SCHEMBL1348719 | 0.85 | SLC6A9 (0.57) | SLC6A9SLC6A5 | |
| SCHEMBL1348705 | 0.84 | SLC6A9 (0.44) | SLC6A9SLC6A5 | |
| SCHEMBL3239665 | 0.84 | SLC6A9 (0.56) | SLC6A9SLC6A5GAAKMT2A | |
| SCHEMBL3234727 | 0.83 | SLC6A9 (0.56) | SLC6A9SLC6A5GAAKMT2AALDH1A1 | |
| SCHEMBL1349513 | 0.82 | SLC6A9 (0.56) | SLC6A9SLC6A5 | |
| SCHEMBL3237902 | 0.82 | SLC6A9 (0.56) | SLC6A9SLC6A5ALDH1A1HPGD | |
| SCHEMBL1349692 | 0.81 | SLC6A9 (0.55) | SLC6A9SLC6A5 | |
| SCHEMBL1350146 | 0.81 | SLC6A9 (0.45) | SLC6A9SLC6A5GAAKMT2AMEN1 | |
| SCHEMBL1349517 | 0.79 | SLC6A9 (0.42) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | claimed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | GLRA1, GLRA2, GRIA1 | SLC6A9 20/4885SLC6A5 10/4885GAA 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.